By Maggie Fick SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on ...

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

London: British pharmaceutical giant AstraZeneca on Tuesday said trading of its shares on the New York Stock Exchange will start from February, in ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

To get full control of C-CAR031, AZ is buying out AbelZeta's 50% share of the China development and commercialisation rights ...

The San Diego firm took a step in that direction on Tuesday, when it unveiled what it says will be the world’s largest ...

Giving in to President Donald Trump’s demands for far higher NHS drug payments would be a “huge backwards step”, the new head ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...